Automated cell counters are instruments that automatically analyze and count microscopic biological cells suspended in liquid, such as blood or plant suspension. Cell counters help scientists and researchers in various biomedical applications such as disease diagnosis, drug development, and other life science research activities. The advantages of automated cell counters include rapid analysis, accuracy and consistency in results, and reduced chances of human errors. With the growing research in fields of cancer, stem cells, and microbiology, the need for cell counting tools has increased significantly.

The Global Automated Cell Counters Market is estimated to be valued at US$ 3.75 Bn in 2024 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023 to 2030.

Key Takeaways
Key players operating in the Automated Cell Counters market are Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer Inc., Bio-Rad Laboratories, BD, Merck KGaA, Logos Biosystems, Corning Incorporated, and Tecan.
The key opportunities in the market include increasing research funding for cell-based studies, advances in microfluidic-based cell counting technologies, and growing stem cell therapy and clinical trials.
Global expansion of key players through mergers and acquisitions is helping increase the geographic footprint. Thermo Fisher Scientific acquired clinical next-generation sequencing company, Novaseq, and Germany-based liquid biopsy company, Predicine, to expand their product portfolio and presence in Europe.

Market Drivers
Increasing research activities in life sciences: The growing research in areas of immunology, microbiology, cancer and stem cells is driving the demand for automated instruments like cell counters for various applications such as cell proliferation assays, cell viability and density measurements.
Advancements in cell separation and analysis technologies: Continuous innovation in microfluidics sector has increased portability and reduced costs of cell counting devices. Miniaturization is improving efficiency and analytical power of automated cell counters.

Market Restraints
High costs of technologically advanced cell counters: The prices of high-throughput, high-parametric cell counters integrated with advanced features like connectivity and imaging technologies are on the higher side. This limits their adoption, especially in academic and research institutes operating with limited budgets.
Lack of skilled professionals: Efficient operation of sophisticated automated cell counters requires trained lab technicians familiar with intricacies of different assay procedures and cell analysis platforms. Shortage of skilled operators poses a challenge.

Segment Analysis

The flow cytometer sub segment dominates the automated cell counters market currently. Flow cytometers offer advantages like simultaneous multiparameter analysis of physical and chemical characteristics of up to thousands of cells per second. Automated cell counting from complex biological samples is done efficiently and accurately using flow cytometer systems. Cell viability assessment is also possible using appropriate fluorescent dyes and reagents. This has increased its use in applications ranging from research to clinical immunology and hematology analysis making it the largest sub segment currently.

Global Analysis

North America region dominates the global automated cell counters market currently accounting for over 35% revenue share currently. Presence of major players, sophisticated research infrastructure, growing clinical adoption and stringent regulatory environment are driving the market in the region. Asia Pacific is expected to be the fastest growing region during the forecast period owing to rising healthcare investments, increasing research focus and improving access to advanced diagnostic technologies. Countries like China, India, Japan and South Korea are expected to offer high growth opportunities supported by improving research funding, growing biopharmaceutical industry and rising affluence.